Trial Profile

Phase 1 study of BC3448

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BC 3448 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

07 Aug 2023 According to a Biocity Biopharmaceutics Media Release, this Phase I trial of BC3448 conducted in China has completed several dose-escalation cohorts and shown a favorable safety profile
20 Jun 2023 New trial record
13 Jun 2023 According to a WuXi Biologics Media Release, the phase I clinical study of BC3448 (CD3/EGFR bispecific antibody) completed the administration of the first subject in China

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com